Laurent Deblir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Laurent Deblir has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Amira Doudou
ABL Diagnostics, 33 Chemin de l’Argile, Floor 3, 13010 Marseille, France
3 shared publications - Rezak Drali
Plateforme Génomique - Bioinformatique, Institut Pasteur d'Algérie, 16302, Algiers, Algeria
3 shared publications - Sofiane Mohamed
ABL Diagnostics, 33 Chemin de l’Argile, Floor 3, 13010 Marseille, France
3 shared publications - Chalom Sayada
ABL SA, 2550 Luxembourg, Luxembourg
2 shared publications - Dimitri Gonzalez
ABL Diagnostics, 33 Chemin de l’Argile, Floor 3, 13010 Marseille, France
2 shared publications - Ronan Boulmé
ABL Diagnostics, 72C Route de Thionville, 57140 Woippy, France
2 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1090
Single-Run Consolidation of Targeted Next-Generation Sequencing Assays for Pathogen Identification, Genotyping, and Antimicrobial Resistance Profiling on the DNBSEQ-E25 Platform: A Proof-of-Concept Study
Background/Objectives: Routine diagnostic microbiology relies on separate workflows for pathogen identification, resistance genotyping, and molecular surveillance. This proof-of-concept study evaluated the feasibility of consolidating targeted assays for bacterial pathogens and DNA and RNA viruses within a single DNBSEQ-E25 sequencing run coupled with automated bioinformatic interpretation. Methods: Twenty-five libraries generated from 21 unique external quality assessment materials, reference strains, and anonymized residual clinical specimens were analysed. Targeted assays covered Mycobacterium tuberculosis resistance-associated regions, human immunodeficiency virus type 1 (HIV-1), cytomegalovirus (CMV), full-length bacterial 16S rRNA, and influenza A/B. Outcomes included on-target sequencing yield, coverage, and pathogen-specific resistance and typing results. Results: The 25 libraries generated 39,962,528 reads, with 82.6% mapping to the intended targets. Both tuberculosis materials yielded resistance profiles concordant with the expected results. HIV-1 pol libraries achieved complete target coverage, whereas whole-genome coverage reached 89.4–91.1%. Both cytomegalovirus formats achieved complete target coverage except for UL54 in the multiplex format, reflecting substantial UL54 depth imbalance. Bacterial 16S results were consistent with the reference organisms, and influenza sequencing enabled subtype and clade assignment. Conclusions: These findings support the technical feasibility of consolidating the evaluated targeted assays within a single DNBSEQ-E25 run. The limited sample set and absence of replicate runs preclude conclusions regarding reproducibility or clinical performance.
- 3 November 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1090
Open AccessSingle-Run Consolidation of Targeted Next-Generation Sequencing Assays for Pathogen Identification, Genotyping, and Antimicrobial Resistance Profiling on the DNBSEQ-E25 Platform: A Proof-of-Concept Study
Background/Objectives: Routine diagnostic microbiology relies on separate workflows for pathogen identification, resistance genotyping, and molecular surveillance. This proof-of-concept study evaluated the feasibility of consolidating targeted assays for bacterial pathogens and DNA and RNA viruses within a single DNBSEQ-E25 sequencing run coupled with automated bioinformatic interpretation. Methods: Twenty-five libraries generated from 21 unique external quality assessment materials, reference strains, and anonymized residual clinical specimens were analysed. Targeted assays covered Mycobacterium tuberculosis resistance-associated regions, human immunodeficiency virus type 1 (HIV-1), cytomegalovirus (CMV), full-length bacterial 16S rRNA, and influenza A/B. Outcomes included on-target sequencing yield, coverage, and pathogen-specific resistance and typing results. Results: The 25 libraries generated 39,962,528 reads, with 82.6% mapping to the intended targets. Both tuberculosis materials yielded resistance profiles concordant with the expected results. HIV-1 pol libraries achieved complete target coverage, whereas whole-genome coverage reached 89.4–91.1%. Both cytomegalovirus formats achieved complete target coverage except for UL54 in the multiplex format, reflecting substantial UL54 depth imbalance. Bacterial 16S results were consistent with the reference organisms, and influenza sequencing enabled subtype and clade assignment. Conclusions: These findings support the technical feasibility of consolidating the evaluated targeted assays within a single DNBSEQ-E25 run. The limited sample set and absence of replicate runs preclude conclusions regarding reproducibility or clinical performance.
- Open Access
Unified Amplicon-Based Whole-Genome Sequencing of Influenza, RSV, and SARS-CoV-2 from Routine Diagnostics: Performance and Clinically Relevant Variant Reporting
Background/Objectives: Influenza, RSV, and SARS-CoV-2 co-circulate and evolve under immune and therapeutic pressures, complicating decision-making for both vaccine formulation and antiviral use. Fragmented, pathogen-specific sequencing approaches limit cross-virus comparability. Methods: We applied a standardized, multiplexed, amplicon-based next-generation sequencing (NGS) workflow to 34 diagnostic specimens (Ct < 35) positive for influenza A/B, RSV-A/B, or SARS-CoV-2. Sequencing libraries were generated and run on an Illumina MiSeq platform (2 × 250 bp). Although the wet-lab workflow is standardized across pathogens, consensus generation and annotation utilized two different analysis environments: Geneious Prime for influenza and MicrobioChek for RSV and SARS-CoV-2. Quality metrics included genome breadth and depth of coverage. Results: Near-complete genomes (mean coverage ≥98%) were recovered for all samples. Influenza A(H1N1)pdm09 sequences clustered in clade 6B.1A; A(H3N2) clustered in subclade 3C.2a1b.2a.2; and influenza B belonged to the Victoria lineage V1A.3a.2. RSV sequences were assigned to Nextclade clades A.D.5.1, A.D.1.10, A.D.2.1, and A.D.3 (RSV-A) and to B.D.4.1.3 and B.D.E.1 (RSV-B), consistent with the ON1 (RSV-A) and BA (RSV-B) genotypes prevalent in recent seasons. Clinically relevant mutations included changes in the influenza HA site and neuraminidase substitutions, RSV F-protein polymorphisms, and spike protein substitutions associated with recent Omicron sublineages (L455F/S, F456L) in SARS-CoV-2. Conclusions: A unified amplicon–NGS approach yields harmonized genomic data across respiratory viruses, enabling timely detection of antigenic drift and resistance markers while supporting integrated, cross-pathogen surveillance.
Open AccessUnified Amplicon-Based Whole-Genome Sequencing of Influenza, RSV, and SARS-CoV-2 from Routine Diagnostics: Performance and Clinically Relevant Variant Reporting
Background/Objectives: Influenza, RSV, and SARS-CoV-2 co-circulate and evolve under immune and therapeutic pressures, complicating decision-making for both vaccine formulation and antiviral use. Fragmented, pathogen-specific sequencing approaches limit cross-virus comparability. Methods: We applied a standardized, multiplexed, amplicon-based next-generation sequencing (NGS) workflow to 34 diagnostic specimens (Ct < 35) positive for influenza A/B, RSV-A/B, or SARS-CoV-2. Sequencing libraries were generated and run on an Illumina MiSeq platform (2 × 250 bp). Although the wet-lab workflow is standardized across pathogens, consensus generation and annotation utilized two different analysis environments: Geneious Prime for influenza and MicrobioChek for RSV and SARS-CoV-2. Quality metrics included genome breadth and depth of coverage. Results: Near-complete genomes (mean coverage ≥98%) were recovered for all samples. Influenza A(H1N1)pdm09 sequences clustered in clade 6B.1A; A(H3N2) clustered in subclade 3C.2a1b.2a.2; and influenza B belonged to the Victoria lineage V1A.3a.2. RSV sequences were assigned to Nextclade clades A.D.5.1, A.D.1.10, A.D.2.1, and A.D.3 (RSV-A) and to B.D.4.1.3 and B.D.E.1 (RSV-B), consistent with the ON1 (RSV-A) and BA (RSV-B) genotypes prevalent in recent seasons. Clinically relevant mutations included changes in the influenza HA site and neuraminidase substitutions, RSV F-protein polymorphisms, and spike protein substitutions associated with recent Omicron sublineages (L455F/S, F456L) in SARS-CoV-2. Conclusions: A unified amplicon–NGS approach yields harmonized genomic data across respiratory viruses, enabling timely detection of antigenic drift and resistance markers while supporting integrated, cross-pathogen surveillance.
- Open Access
Advancing Drug Resistance Detection: Comparative Analysis Using Short-Read and Long-Read Next-Generation Sequencing Technologies
In recent years, antiviral therapy has proved crucial in the treatment of infectious diseases, particularly infections by highly variable viruses such as human immunodeficiency virus, hepatitis B, hepatitis C, SARS-CoV-2 or bacteria such as Mycobacterium tuberculosis. Under the effect of selection pressure, this variability induces mutations that lead to resistance to antiviral and antibacterial drugs, and thus to escape from treatment. The use of Advanced Biological Laboratories (ABL) assays technology combined with next-generation sequencing (NGS) and automatized software to detect majority and minority variants involved in treatment resistance has become a mainstay for establishing therapeutic strategies. The present study demonstrated high concordance between majority and minority subtypes and mutations identified in 15 samples across four NGS platforms: ISeq100 (Illumina (San Diego, CA, USA)), MiSeq (Illumina), DNBSEQ-G400 (MGI (Santa Clara, CA, USA)) and Mk1C MinION (Oxford Nanopore (Oxford Science Park, UK)). However, nanopore technology showed a higher number of minority mutations (® bioinformatics software, compatible with all four sequencing platforms. This study underlines the constant evolution of microbiological diagnostic research and the need to adapt rapidly to improve patient care.
Open AccessAdvancing Drug Resistance Detection: Comparative Analysis Using Short-Read and Long-Read Next-Generation Sequencing Technologies
In recent years, antiviral therapy has proved crucial in the treatment of infectious diseases, particularly infections by highly variable viruses such as human immunodeficiency virus, hepatitis B, hepatitis C, SARS-CoV-2 or bacteria such as Mycobacterium tuberculosis. Under the effect of selection pressure, this variability induces mutations that lead to resistance to antiviral and antibacterial drugs, and thus to escape from treatment. The use of Advanced Biological Laboratories (ABL) assays technology combined with next-generation sequencing (NGS) and automatized software to detect majority and minority variants involved in treatment resistance has become a mainstay for establishing therapeutic strategies. The present study demonstrated high concordance between majority and minority subtypes and mutations identified in 15 samples across four NGS platforms: ISeq100 (Illumina (San Diego, CA, USA)), MiSeq (Illumina), DNBSEQ-G400 (MGI (Santa Clara, CA, USA)) and Mk1C MinION (Oxford Nanopore (Oxford Science Park, UK)). However, nanopore technology showed a higher number of minority mutations (® bioinformatics software, compatible with all four sequencing platforms. This study underlines the constant evolution of microbiological diagnostic research and the need to adapt rapidly to improve patient care.